AU2019272577B2 - Dantrolene formulations and methods of their use - Google Patents

Dantrolene formulations and methods of their use Download PDF

Info

Publication number
AU2019272577B2
AU2019272577B2 AU2019272577A AU2019272577A AU2019272577B2 AU 2019272577 B2 AU2019272577 B2 AU 2019272577B2 AU 2019272577 A AU2019272577 A AU 2019272577A AU 2019272577 A AU2019272577 A AU 2019272577A AU 2019272577 B2 AU2019272577 B2 AU 2019272577B2
Authority
AU
Australia
Prior art keywords
dantrolene
pharmaceutical composition
pharmaceutically acceptable
aspects
disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019272577A
Other languages
English (en)
Other versions
AU2019272577A1 (en
Inventor
Jill COGHLAN
Charles WESCOTT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eagle Pharmaceuticals Inc
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of AU2019272577A1 publication Critical patent/AU2019272577A1/en
Application granted granted Critical
Publication of AU2019272577B2 publication Critical patent/AU2019272577B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019272577A 2018-05-21 2019-05-21 Dantrolene formulations and methods of their use Active AU2019272577B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862674394P 2018-05-21 2018-05-21
US62/674,394 2018-05-21
PCT/US2019/033260 WO2019226621A1 (en) 2018-05-21 2019-05-21 Dantrolene formulations and methods of their use

Publications (2)

Publication Number Publication Date
AU2019272577A1 AU2019272577A1 (en) 2020-11-26
AU2019272577B2 true AU2019272577B2 (en) 2024-08-08

Family

ID=66821419

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019272577A Active AU2019272577B2 (en) 2018-05-21 2019-05-21 Dantrolene formulations and methods of their use

Country Status (15)

Country Link
US (1) US20210236467A1 (https=)
EP (1) EP3796889A1 (https=)
JP (2) JP7762489B2 (https=)
KR (1) KR20210011961A (https=)
CN (1) CN112135605A (https=)
AU (1) AU2019272577B2 (https=)
BR (1) BR112020023012A2 (https=)
CA (1) CA3101093A1 (https=)
IL (1) IL278575B1 (https=)
MA (1) MA52707A (https=)
MX (2) MX2020012464A (https=)
SG (1) SG11202011121UA (https=)
UA (1) UA127661C2 (https=)
WO (1) WO2019226621A1 (https=)
ZA (1) ZA202006986B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419795A (zh) * 2020-05-09 2020-07-17 上药东英（江苏）药业有限公司 一种注射用丹曲林钠混悬剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143677A1 (en) * 2001-06-23 2017-05-25 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2019175761A1 (en) * 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1361092A (en) 1992-03-10 1993-10-05 Kyukyu Pharmaceutical Co., Ltd. Pharmaceutical preparation for percutaneous administration
JPH06263636A (ja) * 1993-03-12 1994-09-20 Kiyoshi Kataoka 脳または高次神経疾患治療剤
EP1603513B1 (en) * 2003-03-04 2020-12-30 Lyotropic Therapeutics, Inc. Dantrolene compositions
WO2010126818A1 (en) * 2009-04-27 2010-11-04 Usworldmeds Llc Intranasal delivery system for dantrolene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143677A1 (en) * 2001-06-23 2017-05-25 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2019175761A1 (en) * 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KRAUSE, T. et al., ‘Dantrolene – A review of its pharmacology, therapeutic use and new developments’, Anaesthesia, 2004, Vol. 59, No. 4, pages 364-373 *

Also Published As

Publication number Publication date
MA52707A (fr) 2021-03-31
JP2021524855A (ja) 2021-09-16
CN112135605A (zh) 2020-12-25
ZA202006986B (en) 2024-04-24
MX2025002392A (es) 2025-04-02
IL278575A (https=) 2021-01-31
IL278575B1 (en) 2026-03-01
UA127661C2 (uk) 2023-11-22
JP2024023270A (ja) 2024-02-21
CA3101093A1 (en) 2019-11-28
SG11202011121UA (en) 2020-12-30
AU2019272577A1 (en) 2020-11-26
BR112020023012A2 (pt) 2021-02-02
KR20210011961A (ko) 2021-02-02
JP7762489B2 (ja) 2025-10-30
MX2020012464A (es) 2021-02-09
EP3796889A1 (en) 2021-03-31
WO2019226621A1 (en) 2019-11-28
US20210236467A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
US20170224789A1 (en) Stable injectable composition of bivalirudin and process for its preparation
EP2654719A1 (en) Aqueous solution of ambroxol
US12419886B2 (en) Parenteral formulations and uses thereof
US9993464B2 (en) Otamixaban formulations with improved stability
EP2666463A1 (en) Stabilized liquid composition comprising pemetrexed
AU2019272577B2 (en) Dantrolene formulations and methods of their use
EP2804597A1 (en) Aqueous paracetamol composition for injection
US9801859B2 (en) Bendamustine formulations
US8178489B2 (en) Formulation for aviptadil
US12208086B2 (en) Stable pharmaceutical compositions of bendamustine
RU2809143C2 (ru) Композиции дантролена и способы их применения
US20140107130A1 (en) Oral Solution Formulations of Aripiprazole
KR20230175221A (ko) 테트로도톡신 액체 제형
US11925703B1 (en) Liquid composition comprising glucose
US11826466B2 (en) Bendamustine solution formulations
US20090029911A1 (en) Liquid Human Growth Hormone Formulation Containing Polyethylene Glycol
US20240180935A1 (en) Solution formulation of cyclophosphamide
US20250255804A1 (en) Liquid injectable compositions of lurbinectedin

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)